Comprising less than 1% of all the adult malignancies, and inflicting pain in more than one body organ, the rarity and heterogeneity of sarcomas make it difficult to diagnose, treat and run a clinical trial resulting in efficient outcomes. The reason, why Soft tissue sarcoma market (STS market) has limited treatment options leaving the small part of the population living with STS helpless.
At present, there exist more than 50 histological forms of Soft tissue sarcoma, as per WHO.
According to a survey done by AACR Project GENIE, the most understood underlying cause of Soft tissue sarcoma is altered genes; and the genes mostly harboring mutation, hence res...
